01 Liquid Biopsy Moving Deeper into Cancer Monitoring Circulating tumor DNA is giving clinicians a less invasive way to track molecular signs of cancer after treatment. This transition is moving liquid biopsy beyond initial tumor profiling toward minimal residual disease assessment and therapy monitoring; in May 2026, the FDA approved Natera’s Signatera CDx for ctDNA-based molecular residual disease detection in muscle-invasive bladder cancer. The result is a broader role for blood testing in precision oncology, post-treatment surveillance, and treatment planning.
02 Multi-Cancer Detection Expanding the Scope of Blood-Based Screening Cell-free DNA analysis is allowing one blood sample to be assessed for molecular signals linked with several cancer types. This transition is bringing methylation-based testing into broader screening research; in September 2026, the FDA scheduled an advisory committee review of GRAIL’s Galleri test, which is designed to identify cancer-specific methylation patterns and predict the likely tissue of origin. The result is a wider screening role for blood testing, with potential to support earlier investigation across multiple cancers from a single test.
01 Higher Burden of Chronic and Metabolic Diseases and Expansion of Point-of-Care Blood Testing Drive Market The high burden of diabetes, cardiovascular disease, kidney disorders, and other chronic conditions increases demand for routine blood testing used in diagnosis and ongoing disease monitoring. WHO’s 2025 NCD update identifies cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes as the major causes of premature NCD deaths, reinforcing the need for regular detection and screening. Blood glucose, HbA1c, lipid, renal-function, and related tests therefore generate recurring testing volumes across hospitals and diagnostic laboratories. Wider availability of point-of-care testing increases the supply of blood-testing services outside centralized laboratories, particularly across clinics, emergency departments, and primary-care settings. Compact systems allow healthcare providers to obtain results closer to the patient and reduce dependence on laboratory sample transport for selected tests. The FDA’s current CLIA-waived test database includes blood-related analytes such as glucose, cholesterol, creatinine, platelet count, and prothrombin time, illustrating the expanding range of tests that can be performed in simpler testing environments. This supply-side transition broadens testing access and increases the number of settings capable of performing routine blood analysis.
01 Shortage of Skilled Laboratory Professionals and Reimbursement and Affordability Constraints Restrain Market Expansion Limited availability of trained technicians, pathologists, and laboratory specialists reduces the capacity of facilities to process and interpret blood tests efficiently. Staff shortages can increase turnaround times, workload, and operating costs, particularly in smaller and underserved healthcare settings. This workforce gap restricts testing capacity and slows broader market expansion.Limited or inconsistent reimbursement for specialized blood tests can increase out-of-pocket costs for patients and budget pressure for healthcare providers. This affordability barrier restricts testing volumes and slows wider adoption.
01 Development of Companion Diagnostic Blood Tests for Targeted Therapies and Expansion of Blood Testing in Transplant Compatibility and Post-Transplant Monitoring Diagnostic companies, pharmaceutical partners, molecular testing laboratories, and precision-medicine providers represent the main players for this opportunity. Companion blood tests can create revenue through therapy-linked assays, co-development agreements, laboratory services, and recurring testing across treatment pathways. Companies such as Roche, QIAGEN, and Guardant Health are well positioned through their precision diagnostics and oncology testing capabilities.Transplant diagnostics companies, hospital laboratories, immunology specialists, and reference laboratories form the key commercial groups for this opportunity. Specialized blood tests can create revenue through HLA typing, immune-status assessment, rejection-risk monitoring, and repeat post-transplant testing services. Companies such as Thermo Fisher Scientific, Bio-Rad, and CareDx are positioned to benefit through established transplant diagnostics and monitoring portfolios.
01 Maintaining Test Accuracy Across Complex and High-Throughput Workflows and Data Interoperability and Fragmented Laboratory Information Systems Blood testing providers must maintain consistent analytical performance across large sample volumes, different specimen conditions, instruments, and testing environments. Errors in calibration, sample handling, or assay performance can trigger repeat testing, recalls, and weaker clinician confidence, making scale-up harder. In 2025, Cepheid recalled its Xpert BCR-ABL Ultra assay because specimens with very high white blood cell counts could produce inaccurate results.Modern blood testing increasingly depends on seamless data exchange among analyzers, laboratory information systems, electronic health records, and point-of-care platforms. Fragmented data structures and weak interoperability can delay result reporting, complicate automation, and raise implementation workloads for laboratories and diagnostic companies. These integration gaps make it harder for market players to scale connected testing networks efficiently across multiple healthcare settings.
September 2025 Danaher expanded its diagnostics capabilities through its operating companies by advancing blood testing platforms and laboratory technologies for clinical diagnostics, immunology, and molecular testing applications.
July 2025 Siemens Healthineers expanded its laboratory diagnostics portfolio with advancements in blood testing technologies, including automation and digital workflow solutions designed to improve laboratory efficiency and clinical decision-making.
June 2025 Abbott expanded its blood diagnostics portfolio by introducing enhancements to laboratory testing systems and point-of-care solutions, supporting applications in infectious disease, cardiovascular health, and routine clinical testing.
May 2025 Roche expanded its diagnostics portfolio by advancing blood testing solutions through improvements in laboratory automation, immunoassay technologies, and clinical diagnostic platforms to support faster and more accurate disease detection.